Calpain 1 inhibitor BDA-410 ameliorates α-klotho-deficiency phenotypes resembling human aging-related syndromes

Sci Rep. 2014 Aug 1:4:5847. doi: 10.1038/srep05847.

Abstract

Taking good care of elderly is a major challenge of our society, and thus identification of potential drug targets to reduce age-associated disease burden is desirable. α-klotho(-/-) (α-kl) is a short-lived mouse model that displays multiple phenotypes resembling human aging-related syndromes. Such ageing phenotype of α-kl(-/-) mice is associated with activation of a proteolytic enzyme, Calpain-1. We hypothesized that uncontrolled activation of calpain-1 might be causing age-related phenotypes in α-kl-deficient mice. We found that daily administration of BDA-410, a calpain-1 inhibitor, strikingly ameliorated multiple aging-related phenotypes. Treated mice showed recovery of reproductive ability, increased body weight, reduced organ atrophy, and suppression of ectopic calcifications, bone mineral density reduction, pulmonary emphysema and senile atrophy of skin. We also observed ectopic expression of FGF23 in calcified arteries of α-kl(-/-) mice, which might account for the clinically observed association of increased FGF23 level with increased risk of cardiovascular mortality. These findings allow us to propose that modulation of calpain-1 activity is a potential therapeutic option for delaying age-associated organ pathology, particularly caused by the dysregulation of mineral ion homeostasis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aging*
  • Animals
  • Calpain / antagonists & inhibitors
  • Calpain / metabolism
  • Drug Evaluation, Preclinical
  • Female
  • Fibroblast Growth Factor-23
  • Fibroblast Growth Factors / blood
  • Glucuronidase / deficiency*
  • Glucuronidase / genetics
  • Humans
  • Klotho Proteins
  • Male
  • Mice, Knockout
  • Phenotype
  • Renal Insufficiency, Chronic / drug therapy
  • Renal Insufficiency, Chronic / genetics
  • Renal Insufficiency, Chronic / metabolism
  • Sulfonamides / pharmacology*
  • Sulfonamides / therapeutic use
  • Vascular Calcification / blood
  • Vascular Calcification / drug therapy

Substances

  • FGF23 protein, human
  • Fgf23 protein, mouse
  • N-1-(hydroxy(3-oxo-2-phenyl-1-cyclopropen-1-yl)methyl)-2-methylpropyl-2-benzenesulfonylamino-4-methylpentanamide
  • Sulfonamides
  • Fibroblast Growth Factors
  • Fibroblast Growth Factor-23
  • Glucuronidase
  • Klotho Proteins
  • Calpain
  • Capn1 protein, mouse